D
Madrigal Pharmaceuticals, Inc. MDGL
$314.39 -$12.71-3.89%
Recommendation
Sell
Prev Close
$314.39
Volume
343,544
Avg Vol (90D)
377,489
Market Cap
$6.94B
Dividend & Yield
--
52-Week Range
$189.00 - $377.46
P/E (TTM)
--
EPS (TTM)
-$22.11
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Good
Volatility Index
Weak
Dividend Index
--
Headlines
Madrigal Pharmaceuticals (MDGL, $314.39) price may climb as it broke lower Bollinger Band on Apr 04, 2025
4/5/2025 - Tickeron - Stocks
Bryce Point Capital LLC Buys Shares of 1,903 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/5/2025 - MarketBeat
Madrigal Pharmaceuticals (MDGL, $327.1) price exceeded its 50-day Moving Average on April 03, 2025
4/4/2025 - Tickeron - Stocks
Madrigal Pharmaceuticals (MDGL, $334.6) price moved above its 50-day Moving Average on April 02, 2025
4/3/2025 - Tickeron - Stocks
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Purchased by Groupama Asset Managment
4/3/2025 - MarketBeat
KLP Kapitalforvaltning AS Invests $802,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
4/2/2025 - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Brokerages
3/30/2025 - Ticker Report
Pictet Asset Management Holding SA Raises Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
3/30/2025 - Ticker Report
Madrigal Pharmaceuticals (MDGL, $327.87) price exceeded its 50-day Moving Average on March 28, 2025
3/29/2025 - Tickeron - Stocks
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?
3/28/2025 - Insider Monkey
Madrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?
3/28/2025 - Zacks Investment Research
Madrigal Pharmaceuticals (MDGL, $337.27) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 27, 2025
3/28/2025 - Tickeron - Technical Analysis
20 Most Expensive Stocks Insiders Are Dumping In March
3/26/2025 - Insider Monkey
Analysts Expect Breakeven For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Before Long
3/25/2025 - Simply Wall St
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Knights of Columbus Asset Advisors LLC
3/23/2025 - Ticker Report
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of "Moderate Buy" from Analysts
3/23/2025 - MarketBeat
Swiss National Bank Buys 600 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
3/22/2025 - Ticker Report
Madrigal Pharmaceuticals (MDGL, $335.13) entered Uptrend as Momentum indicator ascends above 0 level on Mar 20, 2025
3/21/2025 - Tickeron - Stocks
Commit To Purchase Madrigal Pharmaceuticals At $290, Earn 16.3% Annualized Using Options
3/20/2025 - Stock Options Channel
Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires
3/18/2025 - Insider Monkey
William Blair Investment Management LLC Purchases Shares of 371,771 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
3/18/2025 - MarketBeat
Madrigal Pharmaceuticals (MDGL, $342.44) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 17, 2025
3/18/2025 - Tickeron - Technical Analysis
Raymond James Financial Inc. Takes $16.62 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
3/18/2025 - MarketBeat
Madrigal Pharmaceuticals management to meet with Oppenheimer
3/17/2025 - The Fly
Skandinaviska Enskilda Banken AB publ Has $2.43 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
3/17/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$180.13M
EBITDA (TTM)
-$496.78M
EBIT (TTM)
-$497.87M
Net Income (TTM)
-$465.89M
Balance Sheet
Total Assets (Q)
$1.04B
Total Debt (Q)
$119.57M
Total Liabilities (Q)
$287.86M
Book Value Per Share (Q)
$34.28
Cash Flow
Cash from Operations (TTM)
-$455.57M
Cash from Investing (TTM)
-$274.39M
Cash from Financing (TTM)
$735.06M
Net Change in Cash (TTM)
$5.10M
Filings
Filing Date
Wednesday, February 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.16
7-Day Total Return
-6.78%
30-Day Total Return
-2.41%
60-Day Total Return
-5.70%
90-Day Total Return
-9.52%
Year to Date Total Return
0.19%
1-Year Total Return
29.36%
2-Year Total Return
32.80%
3-Year Total Return
235.96%
5-Year Total Return
377.87%
52-week Low
Apr 26, 2024 - $189.00
52-week High
Feb 26, 2025 - $377.46
Valuation
Market Cap
$6.94B - Mid Cap
Enterprise Value
$6.14B
Price/Sales (TTM)
38.27
Price/Book (Q)
9.17
Dividends and Shares
Shares Outstanding
21.93M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.madrigalpharma.com
Phone Number
267 824 2827
Address
Four Tower Bridge
Suite 200 - 200 Barr Harbor Drive
West Conshohocken, PA 19428
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company... more
NASDAQ 04/04/2025 4:00PM Eastern Quotes delayed
Weiss Ratings